Important Reminder for Regeneron Investors
Levi & Korsinsky, LLP is drawing attention to a crucial deadline that Regeneron Pharmaceuticals, Inc. ('Regeneron' or the 'Company') (NASDAQ: REGN) investors must not overlook. Following allegations of securities fraud, a class action lawsuit has been initiated that pertains to investor losses between certain dates.
Understanding the Class Action Lawsuit
This lawsuit aims to aid shareholders of Regeneron who experienced financial challenges due to alleged misleading statements made by the Company. Specifically, these statements are claimed to have distorted the reality of their business practices regarding the credit card fees associated with one of their major products.
Background of the Allegations
The litigation accuses Regeneron of various misleading practices, including the alleged payment of credit card fees to their distributors. These payments obliged the distributors not to charge customers more for using credit cards when buying Eylea, which in turn manipulated the market perception of Eylea's prices.
Consequences for Investors
As these practices reportedly provided Regeneron with an unfair competitive advantage, the inflated sales figures of Eylea were likely misleading to investors. The ramifications of these allegations could lead to compensation for those who lost money during the specified period.
Next Steps for Affected Shareholders
If you are a shareholder of Regeneron and suffered losses during the time frame noted, it is critical to act promptly. Investors need to submit a request to the Court by the upcoming deadline, which is set for March 10, 2025, to be considered for the lead plaintiff role in the case.
What Does Being a Lead Plaintiff Entail?
Being appointed as a lead plaintiff does not impact your eligibility to recover any potential compensation. It merely allows you to take a more active role in the proceedings. Thus, even if one chooses not to apply for this position, they may still be entitled to share in any recovery the class achieves.
No Financial Risk Involved
The legal representation for investors in this case will come at no cost to them. Those deemed eligible for class membership can seek compensation without any upfront costs or fees. This no-cost structure emphasizes the commitment of Levi & Korsinsky to help those affected by potential corporate misconduct.
Why Choose Levi & Korsinsky?
Levi & Korsinsky has established itself as a leading law firm in securing compensation for shareholders over the past two decades. With a robust history of winning complex securities litigation cases, the firm boasts a dedicated team that is well-equipped to support investors in their pursuit of justice.
Track Record of Success
As one of the top firms recognized for securities litigation, Levi & Korsinsky values its clients and places them at the forefront of their priorities. Their knowledge and resources ensure that investors have the best possible representation in pursuing claims.
Contact Information for Further Inquiries
Investors are encouraged to reach out to the firm for any inquiries related to this lawsuit. You can contact Levi & Korsinsky, LLP, directly at (212) 363-7500 for assistance.
Frequently Asked Questions
What is the deadline to file as a lead plaintiff for the Regeneron lawsuit?
The deadline for filing as a lead plaintiff is March 10, 2025.
Who should consider participating in this lawsuit?
Any investor who suffered a financial loss in Regeneron between the specific dates should consider participation.
Is there a cost involved in joining the lawsuit?
No, participating shareholders can seek compensation without any out-of-pocket costs.
What are the main allegations against Regeneron?
The allegations concern misleading practices related to Eylea pricing and credit card fees that impacted shareholders.
Why is it important to act quickly?
Early action ensures that you can secure your rights and potentially recover losses before the deadline passes.
